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Proinflammatory cytokines have been used for several
years in patients with advanced cancer but their adminis-
tration is typically associated with severe toxicity hamper-
ing their application to therapeutically active regimens.
This problem can be overcome by using immunocytokines
(cytokines fused to antibody or antibody fragments)
which selectively deliver the active cytokine to the tumor
environment. Preclinical and recent clinical results con-
firmed that this approach is a very promising avenue
to go. We designed an immunocytokine consisting of the
scFv(F8) specific to extra-domain A of fibronectin and
the very potent human cytokine interleukin-12 (IL12).
The heterodimeric nature of IL12 allows the engineering
of various immunocytokine formats, based on different
combinations of the two subunits (p35 and p40) together
with the scFv. In comparison to monomeric or homodi-
meric cytokines, the construction of a heterodimeric
immunocytokine poses many challenges, e.g. gene dosing,
stable high-yield expression as well as good manufacture
practice (GMP) purification and characterization. In this
paper, we describe the successful construction, character-
ization and production of the heterodimeric immunocyto-
kine F8-IL12. The positive outcome of this feasibility
study leads now to GMP production of F8-IL12, which
will soon enter clinical trials.
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Introduction
Cytokines are key mediators of innate and adaptive immu-
nity. Many cytokines have been used for therapeutic pur-
poses in patients with advanced cancer, but their
administration is typically associated with severe toxicity,
hampering dose escalation to therapeutically active regimens
and their development as anticancer drugs (Janeway’s
Immunobiology; Fyfe et al., 1995; Eggermont et al., 1996;
Leonard et al., 1997). To overcome these problems, the use
of ‘immunocytokines’ (i.e. cytokines fused to antibodies or
antibody fragments) has been proposed, with the aim to con-
centrate the immune-system stimulating activity at the site of
disease while sparing normal tissues (Savage et al., 1993;
Reisfeld et al., 1997; Dela Cruz et al., 2004; Neri and
Bicknell, 2005; Schrama et al., 2006).
The group of Reisfeld has pioneered the fusion of
interleukin-2 (IL2) at the C-terminal end of the heavy chain
of intact immunoglobulins and has brought these products to
clinical trials in patients with cancer (Osenga et al., 2006).
Our group has focused on the engineering of polypeptides
consisting of individual cytokines fused to antibody frag-
ments in scFv format, in order to reduce the circulatory
half-life of these biopharmaceuticals to a minimum, while
retaining their tumor-homing properties (Neri and Bicknell,
2005; Schliemann and Neri, 2007). For pharmacodelivery
applications, we have mainly focused on antibodies specific
to splice isoforms of fibronectin and of tenascin-C, as these
tumor targets are strongly expressed in the stroma and neo-
vasculature of virtually all cancer types, while being
undetectable in most normal adult tissues (Neri and Bicknell,
2005; Brack et al., 2006; Pedretti et al., 2009; Schliemann
et al., 2009; Schwager et al., 2009). Indeed, we have geneti-
cally fused scFv(L19) (specific to the alternatively spliced
EDB domain of fibronectin; Pini et al., 1998), scFv(F8)
(specific to the EDA domain of fibronectin; Villa et al.,
2008) and scFv(F16) (specific to the A1 domain of
tenascin-C; Brack et al., 2006) to several cytokines and have
brought L19-IL2 (Carnemolla et al., 2002), L19-TNF (Borsi
et al., 2003; Halin et al., 2003), F16-IL2 (Marlind et al.,
2008) and F8-IL10 (Schwager et al., 2009) to Phase I and II
clinical trials. In addition, a number of other immunocyto-
kines have been tested in preclinical models of cancer (Halin
et al., 2002a,b, 2003; Ebbinghaus et al., 2005; Gafner et al.,
2006; Kaspar et al., 2007; Trachsel et al., 2007a).
IL12 is a heterodimeric cytokine, consisting of a p35 and
a p40 subunit covalently linked by a disulfide bridge (Yoon
et al., 2000). IL12 is a critical mediator of cell-mediated
immune responses and plays an essential role in the inter-
actions between the innate and adaptive arms of immunity
acting on natural killer (NK) cells and T cells and enhancing
the generation and activity of cytotoxic lymphocytes. IL12 is
responsible for the priming of Th1 cell responses and the
secretion of large amounts of IFN-g from T cells and NK
cells (Colombo and Trinchieri, 2002). IL12 is required for
resistance to bacterial and intracellular parasites, as well as
for the establishment of organ-specific autoimmunity.
IL12 that has exhibited a potent antitumor and antimeta-
static activity in preclinical studies (Brunda et al., 1993;
Trinchieri, 1997; Tsung et al., 1997; Rodolfo and Colombo,
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1999; Colombo and Trinchieri, 2002). Clinical trials in
patients with cancer have revealed promising therapeutic
activities, but have also shown that recombinant human IL12
is extremely toxic to humans, with a maximal tolerated dose
of 0.5 mg/kg of body weight (Atkins et al., 1997; Gollob
et al., 2000).
We have previously reported that the tumor-homing per-
formance and the antitumor activity of recombinant IL12 can
be dramatically improved by fusion to suitable tumor-
targeting antibody fragments, such as scFv(L19) (Halin
et al., 2002b, 2003). The targeted delivery of the murine
IL12 to the tumor site by the fusion to an scFv(L19) moiety
markedly enhanced the antitumor activity of this cytokine in
several models of mice bearing different aggressive murine
tumors (Halin et al., 2002b). The tumor masses in the treated
mice were infiltrated with lymphocytes, macrophages and
NK cells and had elevated IFN-g. The increased therapeutic
activity of IL12 when fused to a tumor-homing antibody,
compared with the minor effect observed when fused to an
irrelevant antibody, showed that therapy correlates with tar-
geting efficiency. Since the fusion of IL12 to scFv(L19) in a
single-chain polypeptide format revealed modest tumor-
targeting performance (Halin et al., 2002b), an engineered
fusion protein with enhanced tumor uptake would display
even more potent anticancer therapeutic properties.
Indeed, the heterodimeric nature of IL12 allows the engin-
eering of various immunocytokine formats, based on differ-
ent combinations of p35, p40 and scFv fusions. In a
comparative biodistribution analysis, we have previously
shown that the heterodimeric scFv-p35/p40-scFv format
(Fig. 1), where both p35 and p40 subunits are genetically
fused to an scFv fragment, displays optimal tumor-targeting
properties and is thus ideally suited for therapeutic appli-
cations (Gafner et al., 2006). However, the cloning,
expression and characterization of this heterodimeric immu-
nocytokine for clinical use poses significant challenges, since
clinical-grade material should not contain the peptidic tags
that were previously used to facilitate purification of the het-
erodimer (Gafner et al., 2006) and since the p35 subunit is
prone to homodimerization. Gene dosage effects on the
expression of heavy and light chain have been found to play
an important role for the high-titer production of IgG
(Schlatter et al., 2005) and this issue becomes even more
important for the expression and purification of heterodi-
meric immunocytokines, where one of the cytokine subunits
can form both homodimers and heterodimers (see also the
‘Results’ section).
In this paper, we describe how the heterodimeric immuno-
cytokine F8-IL12, consisting of scFv(F8) fused to both p35
and p40 subunits of human IL12, could be stably expressed
in mammalian cells and purified to homogeneity with full
retention of cytokine activity. The resulting product exhibited
an impressive tumor-targeting activity in a mouse model of
cancer. ScFv(F8) is particularly suited for tumor-targeting
applications, since the cognate antigen is undetectable in
normal adult tissues (exception made for placenta, endome-
trium and ovaries where physiological angiogenesis takes
place; Schwager et al., 2009) but is strongly expressed not
only in most solid tumors and lymphomas (Villa et al., 2008;
Schliemann et al., 2009), but also on the neovasculature of
tumor metastases (Rybak et al., 2007). F8-IL12 has now
been produced according to good manufacture practice
(GMP) and is now ready for pharmaceutical product
development.
Material and methods
Cloning of F8-p35
For the cloning of F8-p35, the scFv(F8), containing a NheI
restriction site and a leader sequence (Li et al., 1997) at the
50, was amplified by PCR with primer RS9fo (50-ctagctag
cgtcgaccatgggctggagcctgat-30) and NP5ba (50-atcagcgcttccttt
gatttccaccttggtcccttg-30), which appends a part of the human
p35 sequence. Human p35 gene was isolated from a human
cDNA library (Human immune system MTC panel;
Clontech, USA) and was amplified by PCR with primer
NP6fo (50-gtggaaatcaaaggaagcgctgatggaggtagaaac-30) that
Fig. 1. Structure of F8-IL12. (A) Schematic representation of the cloning strategy of the F8-IL12 fusion protein. (B) Protein structure and binding sites of
antigen, protein A, anti-p35 antibody, anti-p70 antibody and anti-p40 antibody.
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appends an overlapping sequence to the VL of scFv(F8) and
RS12ba (50-atagtttagcggccgctcattaggaagcattcagatagctcatcac-
30) which contains two stop codons and a NotI restriction site
at the 30. The scFv(F8) antibody sequence and the human
p35 sequence were PCR assembled. The double-digested
NheI–NotI assembly product was cloned into
the mammalian cell expression vector pcDNA3.1(þ)
(Invitrogen, Switzerland) containing the resistance for
neomycin.
Cloning of p40-F8
For the cloning of p40-F8, the human p40 gene and its
leader sequence were isolated from a human cDNA library
(Human immune system MTC panel; Clontech) and was
PCR amplified with primer KS5fo (50-cccaagcttatgtgtcacca
gcagttggtcatc-30) that anneals on the leader sequence and
introduces a HindIII restriction site at the 50 and RS8ba
(50-cccagactccaacagctgcacctcacctccatcagcgcttccactgca-30) that
contains an overlapping sequence with the scFv(F8). The
scFv(F8) was amplified with primers RS3 (50-gaggtgcagc
tgttggagtctggg-30) which partially overlaps with the sequence
of human p40 and NP7 (50cctttgcggccgctcactatttgatttccacc
ttggtcccttg-30) that introduces two stop codons and a NotI
restriction site. Human p40 and the scFv(F8) sequences were
PCR assembled and double digested with NheI and NotI
restriction enzymes. The digestion product was cloned into
the mammalian cell expression vector pcDNA3.1(þ)
(Invitrogen) containing the resistance for hygromycin. All
PCRs were performed using the High Fidelity Taq
Polymerase (Roche Diagnostics, Germany).
Cell culture
Adherent Chinese hamster ovary (CHO)-S cells were cul-
tured in RPMI 1640 (Gibco, Switzerland) containing 10%
FCS (Invitrogen) and incubated at 378C and 5% CO2.
Suspension CHO-S cells were cultivated in PowerCHO-2 CD
(Lonza, Switzerland) containing 8 mM ultraglutamine
(Lonza, Belgium) incubated at 378C and 5% CO2. When
necessary, G418 (Calbiochem, Germany) and Hygromicin
(Invivogen, Switzerland) were added to the medium at a con-
centration of 0.5 mg/ml.
Generation of a cell line expressing F8-IL12
Adherent CHO-S cells were electroporated using an Amaxa
nucleofector according to the manufacturer’s protocol.
Different ratios of plasmids F8-p35/p40-F8 were used to find
the best conditions to maximize the expression of the hereto-
dimer. Three days after electroporation, stably transfected
cells were selected in the presence of G418 0.5 mg/ml
(Calbiochem) and 0.5 mg/ml hygromycin (Invivogen).
Monoclonal cell lines were obtained by serial dilutions and
screened for expression of the fusion protein by ELISA.
Large-scale culture of F8-IL12 in bioreactor
Stably transfected suspension CHO-S cells driving F8-IL12
expression were grown in PowerCHO-2 CD containing
8 mM ultraglutamine, 0.5 mg/ml G418 and 0.5 mg/ml hygro-
micin. The cell culture inoculum for the 3 l Labfors bio-
reactor (Infors AG, Switzerland) was obtained starting from
a static culture of the cells of the master cell bank. The cell
culture was expanded in roller bottles until cell density
reached 2–3  106 cells/ml. The fed batch fermentation
process was used for the production of F8-IL12. Cells were
seeded at 5  105 cells/ml in the bioreactor. Fixed cell
culture parameters of F8-IL12 in the bioreactor were defined
as 378C temperature, 50% pO2, 130 rpm helical stirring, pH
7.25. Glucose concentration was monitored, and manual
feeds were applied to bring its concentration up to 2 g/l. In
the exponential and plateau growth phase (72–144 h), feeds
of fresh medium supplemented with ultraglutamine were
introduced to maintain cell vitality. In order to monitor the
total protein productivity, 100 ml supernatant samples were
daily collected and affinity purified on HiTrap Protein A
resin (GE Healthcare, Sweden).
Purification of F8-IL12
The fusion protein could be purified from the cell culture
medium by protein A affinity chromatography, as there is a
staphylococcal protein A binding site present on most VH3
domains (Sasso et al., 1991; Hoogenboom and Winter, 1992;
Silacci et al., 2005). Ion exchange chromatography (Ceramic
hyper D; PALL, USA) and preparative size exclusion chrom-
atography on a HiLoad 26/60 Superdex 200 size exclusion
column (GE Healthcare) of the eluted protein A preparation
allowed the isolation of the F8-IL12 heterodimer from a mix
containing also aggregates and polymers.
ELISA of supernatants
ELISA experiments on the conditioned culture media were
performed according to Carnemolla et al. (1996). To detect
different clones expressing F8-IL12, the biotinylated
11-EDA-12 domain of fibronectin, which includes the
epitope recognized by scFv(F8), was immobilized on a
streptavidin-coated plate (StreptaWell, Roche Applied
Bioscience, Germany). Four different detection systems were
used and allowed the evaluation of the expression of the
different components of the fusion protein. Horseradish
peroxidase-conjugated protein A (GE Healthcare), diluted
according to the manufacturer’s recommendations, was used
as agent to detect the VH domain of the fusion protein. In
order to detect the heterodimer p70, the p35 subunit and the
free p40 subunit, three different mouse monoclonal anti-
bodies were used [‘affinity purified antihuman IL12, p35’
(eBioscience, Germany); ‘affinity purified antihuman IL12,
p40’ (eBioscience); ‘antihuman IL12 p70 antibody’ (R&D
Systems, Germany)] and detected with a goat anti-mouse
IgG peroxidase conjugate (Sigma-Aldrich, USA). In all
cases, the immunoreactivity with the immobilized antigen
was detected using the substrate BluePOD (Roche
Diagnostics) for peroxidase, and photometric absorbance at
405 nm was measured.
Bioactivity assay
The biological activity of F8-IL12 was determined by a
T-cell proliferation assay (Gately et al., 2001). Freshly iso-
lated human peripheral blood mononuclear cells were cul-
tured immediately after isolation with 25 mg/ml mitogen
phytohemagglutinin-M (Roche Diagnostics) for 3 days. Cells
were diluted 1:2 by adding equal volume of supplement
medium and further cultivated with 50 IU/ml of human IL2
(Roche Diagnostics). After 24 h, cells were seeded in
96-well plates at a density of 2  104 cells/well in 200 ml of
medium containing serial dilutions of either F8-IL12 or com-
mercially available, recombinant, human IL12 as a standard
Tumor-targeting heterodimeric immunocytokine
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(R&D Systems) or culture medium as a negative control.
After 48 h, 20 ml Cell Titer 96 Aqueous One Solution
(Promega, USA) was added to each well. The plate was incu-
bated for 4 h and absorbance was read at 490 nm. The exper-
iment was performed in triplicate.
Biodistribution studies
The in vivo targeting performance of F8-IL12 was evaluated
by biodistribution analysis as described before (Carnemolla
et al., 2002). Briefly, purified F8-IL12 was radioiodinated
and injected into the tail vein of immunocompetent 129SvEv
mice bearing s.c. implanted F9 murine teratocarcinoma.
Mice were sacrificed 24 or 48 h after injection of the fusion
protein (8 mg, 7 mCi/mouse). Organs were weighed and
radioactivity was counted with a Packard Cobra gamma
counter. Radioactivity content of representative organs was
expressed as the percentage of the injected dose per gram of
tissue (%ID/g).
Microautoradiography
Twenty-four hours after the tail injection of radiolabeled
F8-IL12, mice were sacrificed and tumors were embedded in
paraffin. Ten-micrometer sections were cut and fixed with
paraformaldehyde. Sections were then coated with NBT
KODAK autoradiography emulsion (KODAK, USA), dried
and stored at 48C in the dark for 3 weeks. The autoradiog-
raphy emulsions were developed (Developer D-19, KODAK,
France) and fixed (EASTMAN Fixer, KODAK). Finally,
slides were rinsed with deionized water and counterstained
with hematoxilin (SIGMA, Switzerland).
Mass spectrometry
Following reduction in F8-IL12 with 10 mM TCEP for
30 min at room temperature, the solution was desalted and
concentrated using C4 microcolumns (OMIX
TM tips, Varian
Inc., Paolo Alto, CA, USA) according to the manufacturer’s
guidelines. The reduced and desalted protein was mixed with
sinapinic acid (20 mg/ml in 70% ACN, 0.1% TFA) and
spotted on a MALDI (matrix-assisted laser desorption/ioniz-
ation) target plate. The mass spectrometric analysis was
carried out using a 4800 MALDI-TOF/TOF Analyzer
(Applied Biosystems, Foster City, CA, USA). All spectra
were acquired in the linear mode in a mass range of 10 000–
100 000 m/z with a solid-state laser (355 nm) at a laser rep-
etition rate of 200 Hz. A total of 1500 laser shots were
summed for each spectrum. Spectra were further processed
using the Data Explorer software (Applied Biosystems).
Results
Optimization and stable transfection of cells expressing
F8-IL12
The heterodimeric protein scFv(F8)-p35/p40-scFv(F8) con-
sists of two polypeptides joined together by a disulfide bond
between C74 of p35 and C177 of p40 (Yoon et al., 2000;
Fig. 1B). The C-terminal fusion of scFv(F8) with the p40
subunit is recommended, since the N-terminus of this
subunit should not be chemically modified in order to retain
maximal biological activity (Lieschke et al., 1997). For
immunochemical detection, the scFv moiety can be detected
with a recombinant fibronectin fragment containing the EDA
domain (Villa et al., 2008) and with Protein A (Hoogenboom
and Winter, 1992; Silacci et al., 2005). The p35 subunit is
recognized by monoclonal antibody ‘affinity purified antihu-
man IL12, p35’ (irrespective of whether it is free or paired
with p40 or p35) and the p40 subunit by monoclonal anti-
body ‘affinity purified antihuman IL12, p40’ (only when it is
not associated with p35; Fig. 1B). Furthermore, the heterodi-
meric moiety p70, consisting of the disulfide-linked p35 and
p40, can be detected using monoclonal antibody ‘antihuman
IL12 p70 antibody’.
The genes coding for the two chains, featuring a 14 amino
acid linker (Gly4SerGly4SerGly4) between VH and VL
domain and a 6 amino acid linker (GlySerAlaAspGlyGly)
between scFv and IL12 subunit, were assembled by PCR and
cloned into the pcDNA3.1 expression vectors carrying differ-
ent antibiotic resistance genes, yielding plasmids pRS1a and
pRS1b (Fig. 1A and Supplementary Table S1).
In order to investigate the effect of gene dosage on the
correct assembly and production of F8-IL12, CHO cells were
stably co-transfected with pRS1a and pRS1b used at different
ratios (Fig. 2). The highest protein expression (as assessed by
ELISA with protein-A-based detection) and the highest titer
of heterodimeric protein (as assessed with the antihuman
IL12 p70 antibody) were observed at a pRS1a/pRS1b ratio of
3/7 (Fig. 2). These transfectants were then used for the iso-
lation and characterization of monoclonal cell lines.
Figure 3A shows the results of an ELISA characterization
of culture cell supernatants derived from different mono-
clonal cell lines expressing F8-IL12, which retained the high-
titer formation of heterodimer observed at the polyclonal
level. Clone G11 was used for further subcloning steps and
for stability studies. Figure 3B shows that 26/26 daughter
clones derived from G11 stably produced F8-IL12, as
assessed by anti-p70 ELISA. Subclone 26 was used for cell
bank production according to the GMP guidelines (ICH
guidelines Q5B, Q5C, Q5D).
Production and characterization of F8-IL12
The stable clone 26, driving F8-IL12 expression, was used
for large-scale culture in bioreactor (see also the ‘Material
and methods’ section). A 7-day fed batch fermentation
process was found to be compatible with the production of
F8-IL12. The cell culture was interrupted after 7 days as the
cell viability was drastically decreased (,65%) and no
increase in total protein yield could be observed from the
previous 24-h measurement (Supplementary Fig. S1).
At the end of the fermentation, the culture supernatant was
recovered by cell filtration on vacuum filtration flasks
(Stericups, Millipore) and purified by protein-A chromato-
graphy. The resulting product was further purified by ion
exchange chromatography and size exclusion chromato-
graphy, yielding the final product after a sterile filtration step
with an overall yield of 7 mg/l. This yield is satisfactory, in
consideration of the complex expression of heterodimeric
immunocytokines and of the fact that the maximal tolerated
dose of IL12 in patients is 0.5 mg/kg of body weight which
would correspond to 70 mg of immunocytokine per patient
and administration (yielding 100 doses of fusion protein per
liter production).
The resulting purified F8-IL12 was characterized by SDS–
PAGE analysis, confirming the presence of a single band of
apparent molecular weight equal to 120 kDa in non-reducing
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conditions and of two bands of 55 and 65 kDa in reducing
conditions, as expected (Fig. 4A). The product eluted as a
single peak in size-exclusion chromatography on a
Superdex-200 column, with no evidence of protein aggrega-
tion (Fig. 4B). The heterodimeric F8-IL12 exhibited a high
functional affinity toward the cognate antigen, with flat dis-
sociation profile (apparent koff ¼ 3.3  1024 s21) as assessed
by a real-time interaction analysis on a Biacore 3000 instru-
ment (Fig. 4C).
A mass spectrometric characterization on a 4800
MALDI-TOF/TOF analyzer revealed that the two subunits
F8-p35 and p40-F8 of the heterodimer F8-IL12 have molecu-
lar weights of 53 969+ 88 and 64 246+ 46 Da, respectively
(Fig. 5). We experimentally detected an increased molecular
weight for both subunits (Fig. 5) compared with the calcu-
lated molecular mass of the amino acid sequence (Fig. 5 and
Supplementary Table S1). The difference in molecular
weight for both subunits may be the consequence of a post-
translation glycosylation, in agreement with the previously
reported glycosylation patterns of unmodified IL12 (Carra
et al., 2000). Carra et al. showed that both p40 and p35 sub-
units of IL12 undergo a complex glycosylation modification
which is an essential requirement for the correct folding,
assembly and secretion of the mature heterodimer. Indeed,
the incomplete glycosylation of the p35 and p40 subunits
deeply alter the formation and secretion of the heterodimer
Fig. 2. ELISA on supernatants of co-transfected CHO-S cells with pRS1a and pRS1b at different ratios. The x-axis shows the percentage of pRS1a (F8-p35
plasmid) used. The arrow indicates the highest titer of heterodimeric protein (antihuman IL-12 p70 antibody) that was observed at a pRS1a/pRS1b ratio of 3/7.
Fig. 3. Monoclonal cell lines. (A) ELISA on 11 monoclonal cell line supernatants using four different detection systems. The arrow indicates clone G11
chosen for subcloning. (B) ELISA on 26 monoclonal cell line supernatants with an antihuman IL-12 p70 antibody that recognizes the heterodimeric protein.
The arrow indicates clone 26 that was used for large-scale production of F8-IL12.
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and determines the formation of unsecreted p35 aggregates,
confirming the critic role of the glycosylation for production
and secretion of the mature heterodimer (Carra et al., 2000).
In order to confirm that the engineering of the p70 moiety
into scFv-p35/p40-scFv format (Fig. 1) did not impair the
biological activity of IL12, we compared the immunostimu-
latory properties of recombinant human IL12 and of F8-IL12
in a lymphocyte proliferation assay. The two proteins
exhibited superimposable mitogenic profiles, when plotted
on an equimolar basis, with a half-maximal activity at
600 pM IL12 equivalents (Fig. 6).
Finally, we investigated the tumor-targeting properties of
F8-IL12 by performing a quantitative biodistribution analysis
in mice bearing F9 tumors (Villa et al., 2008) with a radio-
iodinated protein preparation. Cohorts of four mice were
sacrificed 24 and 48 h after intravenous injection, and the
resulting organs and body fluids were weighed and counted.
F8-IL12 selectively accumulated in the tumor, with percent
injected dose per gram (%ID/g) values of 22 and 15 at the
two time points, respectively (Fig. 7A). When correcting for
tumor growth during the experiment (F9 tumors have a dou-
bling time of 40 h; Tarli et al., 1999), one observes a stable
accumulation of immunocytokine in the tumor at high levels
(approx35%ID/g), which is consistent with the inert nature
of EDA-containing fibronectin fibers (Fig. 7B). Furthermore,
an ex vivo microautoradiography of tumors from biodistribu-
tion revealed selective accumulation of the radiolabeled
F8-IL12 protein around tumor vessels (Fig. 7C).
Discussion
In this article, we have described the cloning, expression and
characterization of a novel fully human immunocytokine,
suitable for clinical development programs in patients with
cancer. Compared with monomeric immunocytokines, the
fusion of heterodimeric cytokines to a full antibody or anti-
body fragment presents several biotechnological challenges.
First, multiple formats can be considered for the construction
of fusion proteins, which do not exhibit identical in vivo bio-
distribution properties (Gafner et al., 2006). Moreover,
vector design and gene dosage effects influence the stability
of the resulting stably transfected cell lines and product
quality.
We used the strategy of Gafner et al. (2006) for the
cloning of the heterodimeric cytokine IL12 to the tumor-
targeting antibody fragment scFv(F8). The resulting immu-
nocytokine consists of the disulfide-linked IL12 subunits p35
and p40, each joined to an scFv fragment. In contrast to the
cloning strategy of Gafner et al., we omitted all C-terminal
Fig. 4. Characterization of F8-IL12. (A) SDS–PAGE analysis of the protein
under non-reducing and reducing conditions. (B) Gel filtration analysis
reveals one single peak when analyzed under native conditions for the
heterodimer F8-IL12. (C) Surface Plasmon resonance analysis shows
flat dissociation phase of F8-IL12 (Biacore 3000, flow 20 ml/min, F8-IL12
5  1027 M).
Fig. 5. Mass spectrometric analysis of F8-IL12. Following reduction in the
heterodimer F8-IL12, the two subunits F8-p35 and p40-F8 were identified
by MALDI-TOF mass spectrometry. The determined mass of both subunits
(Mass MS) was considerably higher than the mass calculated according to
the amino acid composition (Mass AA). This difference is due to
glycosylation of the two subunits.
Fig. 6. Bioactivity assay. Comparison of the lymphoproliferative activity of
rhuIL12 (in black) and F8-IL12 (in grey).
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peptide tags, an essential requirement for compatibility with
current GMP guidelines and subsequent clinical development
of this biopharmaceutical. In spite of the complex cloning
strategy with two independent vectors, the absence of pepti-
dic tags for affinity purification and the need for cell line
stability over multiple passages, we were able to generate a
clone expressing the F8-IL12 heterodimer at 7 mg/l. These
yields are compatible with clinical development programs, in
consideration of the fact that the Maximal Tolerated Dose of
IL12 in cancer patients is as low as 0.5 mg/kg of body
weight. The fusion protein retained its full bioactivity as
shown by in vitro proliferation assay and kept its high
binding affinity to the cognate antigen, the alternatively
spliced extradomain A of fibronectin. Biodistribution studies
revealed an impressive tumor uptake of F8-IL12, with excel-
lent tumor to organ ratio. Microautoradiography confirmed
the selective accumulation of F8-IL12 at vascular structures
of the tumor.
Our group has generated and investigated in clinical trials
the human monoclonal antibodies F8, L19 and F16 (Pini
et al., 1998; Brack et al., 2006; Villa et al., 2008), specific to
the alternatively spliced EDA and EDB domains of
Fig. 7. Biodistribution studies. (A) F9 tumor bearing mice were injected intravenously with 125I-labeled F8-IL12 and sacrificed 24 or 48 h after injection.
(B) Tumor values are corrected for tumor growth during the experiment (F9 tumors have a doubling time of 40 h). (C) An ex vivo microautoradiography shows
a selective accumulation of 125I-labeled F8-IL12 around tumor vessels.
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fibronectin and to the alternatively spliced A1 domain of
tenascin-C, respectively. The tumor-targeting properties of
these antibodies have extensively been studied in animal
models of pathology (Carnemolla et al., 2002; Brack et al.,
2006; Kaspar et al., 2007; Marlind et al., 2008; Villa et al.,
2008). In addition, a radioiodinated version of the L19 anti-
body in the scFv format (Santimaria et al., 2003) and in the
SIP format (Sauer et al., 2009) have been studied in imaging
and radioimmunotherapy clinical trials in patients with
cancer. Similar studies are currently being conducted also for
SIP(F16) and SIP(F8).
The clinical-stage L19, F8 and F16 antibodies have been
used as modular building blocks for the construction of
immunocytokines based on IL2 (Carnemolla et al., 2002;
Marlind et al., 2008), IL10 (Trachsel et al., 2007a; Schwager
et al., 2009), IL12 (Halin et al., 2002b; Gafner et al., 2006),
TNF (Borsi et al., 2003), IFN-gamma (Ebbinghaus et al.,
2005), IL15, GM-CSF (Kaspar et al., 2007) and other
cytokines.
IL12-based immunocytokines appear to display potent
antitumor effects, without worsening inflammation in animal
models of chronic autoimmune diseases (Trachsel et al.,
2007b).
At present, the immunocytokines L19-IL2, F16-IL2,
L19-TNF and F8-IL10 are being investigated in multiple
clinical trials at 18 European centers. The development
activities for F8-IL12 described in this article represent the
basis for the future clinical studies of this product.
Investigations in patients with cancer are particularly encour-
aged by the excellent biodistribution results observed with
F8-IL12 (Fig. 7) and by the fact that the EDA domain of
fibronectin is virtually undetectable in normal adult organs,
while being strongly expressed in the majority of aggressive
solid tumors and lymphomas (Pedretti, Rancic et al.; Rybak
et al., 2007; Villa et al., 2008; Schliemann et al., 2009).
Supplementary data
Supplementary data are available at PEDS online.
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